Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EMA Proposes Extending Remote QP Batch Certification Post-Pandemic

Executive Summary

Stakeholders given one month to weigh in on proposal to allow relaxations introduced in response to COVID-19-related travel restrictions to continue on a routine basis.

You may also be interested in...



EFPIA Supports Uniform Approach By EU Member States On Remote Batch Certification

The European federation of research-based drug companies has made suggestions to ensure the consistent adoption of an EU proposal that seeks to continue the flexibilities that were introduced in response to COVID-19-related travel restrictions.

EU Allows Pharma To Temporarily Prioritize Reporting For COVID-19 Adverse Events

Drug companies unable to continue with standard reporting of suspected adverse reactions to the EU pharmacovigilance database can temporarily prioritize their reporting activities to focus on COVID-19 related safety events.

As Annex 16 Revision Proceeds, QPs Urged to Focus on Quality Systems in Certifying Batches

Qualified persons should respond to the complexities of globalization by leveraging quality systems rather than confirming every detail, Pfizer official says. Proposed revision to Annex 16 of EU GMPs defines numerous tasks QPs can delegate.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS146176

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel